Wall Street brokerages expect Pulmonx Co. (NASDAQ:LUNG) to post sales of $13.36 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Pulmonx’s earnings, with the lowest sales estimate coming in at $13.00 million and the highest estimate coming in at $13.71 million. Pulmonx reported sales of $10.61 million in the same quarter last year, which indicates a positive year-over-year growth rate of 25.9%. The business is scheduled to announce its next quarterly earnings report on Tuesday, November 9th.
According to Zacks, analysts expect that Pulmonx will report full year sales of $50.62 million for the current year, with estimates ranging from $50.20 million to $50.92 million. For the next financial year, analysts anticipate that the company will report sales of $77.45 million, with estimates ranging from $74.28 million to $81.80 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow Pulmonx.
Pulmonx (NASDAQ:LUNG) last posted its quarterly earnings results on Monday, August 2nd. The company reported ($0.34) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.03. The business had revenue of $12.20 million for the quarter, compared to the consensus estimate of $10.26 million. Pulmonx had a negative return on equity of 33.72% and a negative net margin of 89.71%.
In related news, CFO Derrick Sung sold 3,000 shares of the stock in a transaction that occurred on Monday, September 20th. The stock was sold at an average price of $37.35, for a total value of $112,050.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Glendon E. French III sold 25,000 shares of the stock in a transaction that occurred on Thursday, August 19th. The stock was sold at an average price of $36.63, for a total value of $915,750.00. The disclosure for this sale can be found here. Insiders have sold 2,624,730 shares of company stock valued at $98,354,637 in the last three months. Insiders own 12.56% of the company’s stock.
A number of institutional investors have recently modified their holdings of LUNG. Greenspring Associates LLC purchased a new position in shares of Pulmonx during the first quarter worth $26,000. Royal Bank of Canada boosted its position in shares of Pulmonx by 119.0% during the first quarter. Royal Bank of Canada now owns 863 shares of the company’s stock worth $40,000 after buying an additional 469 shares during the period. Siguler Guff Advisers LLC purchased a new position in shares of Pulmonx during the second quarter worth $43,000. Citigroup Inc. boosted its position in shares of Pulmonx by 104.5% during the second quarter. Citigroup Inc. now owns 1,575 shares of the company’s stock worth $69,000 after buying an additional 805 shares during the period. Finally, Ameritas Investment Partners Inc. boosted its position in shares of Pulmonx by 104.6% during the second quarter. Ameritas Investment Partners Inc. now owns 1,991 shares of the company’s stock worth $88,000 after buying an additional 1,018 shares during the period. Institutional investors own 70.42% of the company’s stock.
Pulmonx stock traded up $0.99 during trading hours on Friday, hitting $38.50. 8,532 shares of the stock traded hands, compared to its average volume of 356,166. The company has a debt-to-equity ratio of 0.07, a current ratio of 14.28 and a quick ratio of 13.46. The firm’s 50 day moving average price is $39.14 and its 200-day moving average price is $43.15. The stock has a market capitalization of $1.41 billion and a price-to-earnings ratio of -16.17. Pulmonx has a 1 year low of $35.81 and a 1 year high of $69.48.
Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Featured Article: How to Invest in an Index Fund
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.